Biological Agents & Infectious Diseases
Infection Update--294 (
WHO) In the temperate zone of the southern hemisphere, high levels of influenza activity continued to be reported. A few countries in Central America, the Caribbean and South East Asia also reported increased influenza activity. Influenza activity in the temperate zone of the northern hemisphere was reported at low levels. Worldwide, influenza A(H3N2) and B viruses co-circulated.
Go to article
Global Health Security
WHO: Hospital Outbreaks Underscore MERS Challenges (
CIDRAP) Though surveillance for MERS-CoV and response to suspected clusters have improved, especially in hard-hit Saudi Arabia, early identification in the community and in healthcare facilities and compliance with infection prevention and control protocols still pose major challenges, WHO said in its latest risk assessment.
Go to article
Helping the Heroines of Polio Eradication (
Project Syndicate) Last month, world governments and other donors pledged $1.2 billion to help carry the 30-year fight to eradicate polio over the finish line. At its height, the polio epidemic caused 350,000 cases of paralysis in children every year. Last year, only 37 cases were reported. So far this year, the number stands at 6.
Go to article
Medicine & Public Health
Chikungunya Vaccine Trials Begin (
JAMA) A phase 1 and 2 clinical trial of an experimental vaccine against the viral disease chikungunya has begun enrolling a planned 180 healthy adult volunteers aged 18 to 45 years with funding by NIAID.
Go to article
Science & Technology
A Peptide-Based Viral Inactivator Inhibits Zika Virus Infection in Pregnant Mice and Fetuses (
Nature Communications) ZIKV, a re-emerging flavivirus associated with neurological disorders, has spread rapidly to more than 70 countries and territories. However, no specific vaccines or antiviral drugs are currently available to prevent or treat ZIKV infection. Here we report that a synthetic peptide derived from the stem region of ZIKV envelope protein, designated Z2, potently inhibits infection of ZIKV and other flaviviruses in vitro.
Go to article
There's a Promising New HIV Vaccine Candidate in the Pipeline (
Vox) Developing a vaccine to stop HIV is thought to be among the most daunting challenges in medicine for 1 big reason: The virus is extraordinarily genetically diverse, even more so than the flu. So it's difficult to think about how a single shot might work against all the different HIV subtypes circulating around the world.
Go to article
Other 21st Century Threats
|